STOCK PRICE

Discussion in 'Mallinckrodt' started by anonymous, Oct 19, 2017 at 10:08 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Brilliant, well said! This company cannot even get the simple things right.
    Bedminster is a place for big pharma rejects!
    Markie Mark needs to go!
     

  2. anonymous

    anonymous Guest

    What's up with the stock price. Is MNK buying it up? It seems to be defying gravity .
     
  3. anonymous

    anonymous Guest

    Doesn’t make any sense. Will go back down. This is a fraud. OIG, payer issues etc will not turn around.
     
  4. anonymous

    anonymous Guest

    Stocks headed to the moon !
     
  5. anonymous

    anonymous Guest

    Thanks HO. I feel better now. Keep spewing your BS. Sinking ship and you know it!
     
  6. anonymous

    anonymous Guest

    Being captain of a sinking ship pays better than being on the dock with no ship.
     
  7. anonymous

    anonymous Guest

    Welcome to the Titanic! Enjoy the ride!
     
  8. anonymous

    anonymous Guest

    wow our stock is cooking with gas. Up 33% in 10 days!!!!!!!
    We are back baby.
    We have made back all our loses to last month. Only 30 more months of loses and $115 to catch up on
     
  9. anonymous

    anonymous Guest

    Great time to short! Payer coverage for Acthar will only continue to get worst. No way out of this one. Game over!!!
     
  10. anonymous

    anonymous Guest

    Is the company buying back stock? I can't believe after all the bad press that anyone with half a brain would buy this. The shorts have got to be licking their chops.
     
  11. anonymous

    anonymous Guest

    They have to be. No other way the stock is moving up so much. Again another piss poor decision. We are in debt up to our eyeballs. Piled on even more debt for products that didn’t get approved. Acthar sells are declining, margins are shrinking even faster and the buy back stock versus pay debt down and actually invest in the underlying businesses. MNK will have a Valeant like fire sale inside of the next 2 years. If they lose Medicaid coverage for Acthar in February it will be even sooner.
     
  12. anonymous

    anonymous Guest

    it would be a fire sale because none of our products have a clear
    Value with inomax patent loss, acthar coverage issues, oformev
    29 months before generics and so on. Ok, some value in pipeline for 3 products until we try to commercialize them.
    Bonobyi and peds constipaton. Etc to come
     
  13. anonymous

    anonymous Guest

    You shithead shorts and bears should go kill yourself.
     
  14. anonymous

    anonymous Guest

    MNK has a flawed and completely unsustainable business model and that is some how the short sellers issue. I don’t think you understand how the market works.

    Besides that most shorts have cashed in and moved on. Not much meat left on this dead carcass of a company. 90% of the market value is gone.
     
  15. anonymous

    anonymous Guest

    2Q18 earnings out on 8/7. I'll be enjoying the show and raking in the dough...mostly from shorts of course.
     
  16. anonymous

    anonymous Guest

    41% float shorted 33.5M shares. Price going to $60's.
    Enjoying the show!
     
  17. anonymous

    anonymous Guest

    Q2 isn’t where your issue will MNK will show. 60 minutes and subsequent decking in Naive referrals will have a larger impact in Q3 and CNN effects in Q3 and Q4. There are better places to park your money. Far too much risk and not enough upside.
     
  18. anonymous

    anonymous Guest

    MNK is the place to park your money. It's going $60's.
     
  19. anonymous

    anonymous Guest

    Stock down on news of Praxair, looking forward to more competitors. Acthar, Therakos etc. The ship is going like a cheap whore, but then again that's what MNK is!
     
  20. anonymous

    anonymous Guest

    Where has the jackass claiming the stock was going to 60’s been. He’s almost as funny as the ALL CAPS JACKASS!!!